Please Wait
Applying Filters...
menu
    • menu
    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-06-09

    Virtual Booth

    Contact Supplier

    Menu

    Olanzapine (JAN/USAN/INN)

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 835Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Teva Shares Uzedy, TEV-‘749 Data In Schizophrenia At ASCO
    Teva Shares Uzedy, TEV-‘749 Data In Schizophrenia At ASCO

    30 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/31/3091373/0/en/Teva-Presents-Latest-Schizophrenia-Portfolio-Data-Including-Real-World-Outcomes-with-UZEDY-risperidone-Showing-Lower-Rates-of-and-Longer-Time-to-Relapse-Compared-to-Oral-Treatment-.html

    GLOBENEWSWIRE
    30 May 2025
    Share Share
    Qilu Pharma`s Generics Olanzapine Receives Approval in US
    Qilu Pharma`s Generics Olanzapine Receives Approval in US

    16 May 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218116

    FDA
    16 May 2025
    Share Share
    J&J & Lilly Concealed Breast Cancer Risks in Antipsychotics Drug
    J&J & Lilly Concealed Breast Cancer Risks in Antipsychotics Drug

    24 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/jj-and-eli-lilly-concealed-breast-cancer-risks-in-blockbuster-antipsychotics-for-decades-wisner-baum-lawsuit-alleges-302436429.html

    PR NEWSWIRE
    24 Apr 2025
    Share Share
    Teva's Schizophrenia Portfolio Enhanced by Ph 3 Trial Results
    Teva's Schizophrenia Portfolio Enhanced by Ph 3 Trial Results

    31 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/31/3052605/0/en/New-Data-Strengthens-Teva-s-Schizophrenia-Portfolio-Including-Phase-3-SOLARIS-Trial-Survey-Results-Demonstrating-Patient-and-Healthcare-Professional-Satisfaction-with-TEV-749-olanz.html

    GLOBENEWSWIRE
    31 Mar 2025
    Share Share
    Teva Completes Phase 3 Trial For Olanzapine LAI In Schizophrenia
    Teva Completes Phase 3 Trial For Olanzapine LAI In Schizophrenia

    10 Feb 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250209967526/en

    BUSINESSWIRE
    10 Feb 2025
    Share Share
    Sunshine Biopharma launches Olanzapine and Olanzapine ODT
    Sunshine Biopharma launches Olanzapine and Olanzapine ODT

    22 Jan 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/sunshine-biopharma-launches-olanzapine-and-olanzapine-odt-16694

    INDPHARMAPOST
    22 Jan 2025
    Share Share